Retirement Systems of Alabama Has $3.71 Million Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Retirement Systems of Alabama trimmed its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 3.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 85,182 shares of the life sciences company’s stock after selling 3,247 shares during the quarter. Retirement Systems of Alabama owned approximately 0.11% of Integra LifeSciences worth $3,710,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Raymond James & Associates boosted its stake in shares of Integra LifeSciences by 28.7% during the third quarter. Raymond James & Associates now owns 204,325 shares of the life sciences company’s stock valued at $7,803,000 after purchasing an additional 45,554 shares in the last quarter. Strs Ohio boosted its position in Integra LifeSciences by 6.9% during the 3rd quarter. Strs Ohio now owns 41,730 shares of the life sciences company’s stock worth $1,593,000 after buying an additional 2,679 shares during the period. Advisor Partners II LLC bought a new stake in Integra LifeSciences during the 3rd quarter worth approximately $241,000. Inspire Investing LLC increased its position in Integra LifeSciences by 5.1% in the 3rd quarter. Inspire Investing LLC now owns 8,004 shares of the life sciences company’s stock valued at $306,000 after acquiring an additional 392 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Integra LifeSciences by 451.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 70,827 shares of the life sciences company’s stock valued at $2,705,000 after acquiring an additional 57,993 shares during the last quarter. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Trading Up 8.4 %

NASDAQ:IART opened at $25.08 on Wednesday. Integra LifeSciences Holdings Co. has a 12 month low of $22.36 and a 12 month high of $51.12. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94. The stock has a market capitalization of $1.97 billion, a price-to-earnings ratio of 30.22, a PEG ratio of 0.87 and a beta of 1.17. The firm has a fifty day simple moving average of $32.95 and a two-hundred day simple moving average of $38.24.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, meeting the consensus estimate of $0.55. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The company had revenue of $368.90 million during the quarter, compared to the consensus estimate of $361.96 million. During the same period last year, the business posted $0.74 EPS. The firm’s revenue for the quarter was down 3.2% compared to the same quarter last year. Analysts expect that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on IART. Truist Financial decreased their price objective on Integra LifeSciences from $37.00 to $25.00 and set a “hold” rating for the company in a report on Tuesday. Wells Fargo & Company cut Integra LifeSciences from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $45.00 to $25.00 in a research note on Tuesday. Oppenheimer lowered Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research note on Tuesday. JMP Securities decreased their target price on shares of Integra LifeSciences from $49.00 to $40.00 and set a “market outperform” rating for the company in a research report on Tuesday. Finally, Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price target on the stock in a research report on Wednesday, April 3rd. Three research analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Integra LifeSciences presently has an average rating of “Hold” and a consensus target price of $36.80.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.